GlassScriptPhysician profile
Michael Harding Smelser
NPI 1518993567
$1,120.52
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $854 · 2020: $245 · 2022: $21.44.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $212.42 | 2019-2020 | |
| Amgen INC. | $156.28 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $137.08 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $121.15 | 2019-2020 | |
| Lilly USA, LLC | $83.49 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.26 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $67.36 | 2019-2020 | |
| Glaxosmithkline, LLC. | $63.07 | 2019-2020 | |
| Pfizer INC. | $37.59 | 2019 | |
| Amarin Pharma, INC. | $35.95 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.04 | 2019 | |
| Novartis Pharmaceuticals Corporation | $24.88 | 2019 | |
| Sunovion Pharmaceuticals INC. | $23.34 | 2019 | |
| Abbvie INC. | $21.44 | 2022 | |
| Genentech USA, INC. | $20.31 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $12.86 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Smelser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.